Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...